FDA Approves Viral Therapy Plus Nivolumab - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Viral Therapy Plus Nivolumab

Accelerated approval is based on objective response rate and duration of response in advanced melanoma, with postapproval trials required to confirm clinical benefit.

  • By

  • Kathryn Wighton

  • August 7, 2026

  • 2 min

Share

  • 1

    The FDA approved vusolimogene oderparepvec-wtpg plus nivolumab for adults with unresectable advanced cutaneous melanoma.

  • 2

    Approval was based on the objective response rate and duration observed in the IGNYTE trial involving 140 patients.

  • 3

    In the trial, the objective response rate was 24.2%, with a median duration of response of 14.1 months.

  • 4

    Replimune must conduct postapproval trials to verify the clinical benefit of the treatment combination.

  • 5

    Warnings include risks of herpetic infection, injection complications, and various nonlaboratory adverse reactions.

Original Source(s)

FDA Approves Viral Therapy Plus Nivolumab

  • by Kathryn Wighton

  • August 7, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

iNOS is a key mediator of anti-PD-1 melanoma therapy response

Artificial intelligence in three-dimensional total-body photography for skin cancer surveillance